SG11201508017QA - Modulation of structured polypeptide specificity - Google Patents
Modulation of structured polypeptide specificityInfo
- Publication number
- SG11201508017QA SG11201508017QA SG11201508017QA SG11201508017QA SG11201508017QA SG 11201508017Q A SG11201508017Q A SG 11201508017QA SG 11201508017Q A SG11201508017Q A SG 11201508017QA SG 11201508017Q A SG11201508017Q A SG 11201508017QA SG 11201508017Q A SG11201508017Q A SG 11201508017QA
- Authority
- SG
- Singapore
- Prior art keywords
- modulation
- polypeptide specificity
- structured polypeptide
- structured
- specificity
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201306623A GB201306623D0 (en) | 2013-04-11 | 2013-04-11 | Modulation of structured polypeptide specificity |
| PCT/EP2014/057440 WO2014167122A1 (en) | 2013-04-11 | 2014-04-11 | Modulation of structured polypeptide specificity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201508017QA true SG11201508017QA (en) | 2015-10-29 |
Family
ID=48537122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201805806RA SG10201805806RA (en) | 2013-04-11 | 2014-04-11 | Modulation of Structured Polypeptide Specificity |
| SG11201508017QA SG11201508017QA (en) | 2013-04-11 | 2014-04-11 | Modulation of structured polypeptide specificity |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201805806RA SG10201805806RA (en) | 2013-04-11 | 2014-04-11 | Modulation of Structured Polypeptide Specificity |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10118947B2 (en) |
| EP (1) | EP2983722B1 (en) |
| JP (2) | JP6588890B2 (en) |
| CN (1) | CN105307686B (en) |
| AU (1) | AU2014253036B2 (en) |
| CA (1) | CA2908406C (en) |
| DK (1) | DK2983722T3 (en) |
| ES (1) | ES2715406T3 (en) |
| GB (1) | GB201306623D0 (en) |
| NZ (1) | NZ713439A (en) |
| PL (1) | PL2983722T3 (en) |
| PT (1) | PT2983722T (en) |
| RU (1) | RU2674070C2 (en) |
| SG (2) | SG10201805806RA (en) |
| TR (1) | TR201903649T4 (en) |
| WO (1) | WO2014167122A1 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2764140T3 (en) * | 2011-10-07 | 2018-04-30 | Bicyclerd Limited | Modulation of structured polypeptide specificity |
| GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| ES2715379T3 (en) * | 2013-10-28 | 2019-06-04 | Bicyclerd Ltd | Novel Polypeptides |
| CN107148425B (en) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | Bicyclic peptide ligands specific for MT1-MMP |
| EP3444264A4 (en) * | 2016-04-14 | 2020-03-18 | TAO Health Life Pharma Co., Ltd. | PEPTIDE FOR AMYLOSPHEROID BINDING INHIBITION (ASPD), AND ASSESSMENT AND SCREENING METHOD |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| EP3645549A1 (en) * | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP7670481B2 (en) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Bicyclic peptide ligands specific for CD137 - Patent application |
| TWI825046B (en) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Bicyclic peptide ligands specific for epha2 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| CN111902429A (en) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | Multimeric bicyclic peptide ligands |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate comprising the peptide ligand and a pharmaceutical composition comprising the drug conjugate |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| WO2020120984A1 (en) * | 2018-12-13 | 2020-06-18 | Bicycletx Limited | Bicyclic peptide ligands specific for mt1-mmp |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (en) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | Heterotandem bicyclic peptide complex |
| SMT202500247T1 (en) | 2019-10-03 | 2025-09-12 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes |
| WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
| CN115768456A (en) * | 2020-04-06 | 2023-03-07 | 拜斯科技术开发有限公司 | TSLP-specific bicyclic peptide ligands |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
| KR102486996B1 (en) * | 2020-09-04 | 2023-01-10 | 서울대학교병원 | Peptide and composition for improving wrinkle and treating metabolic desease containing the same |
| WO2023144030A1 (en) | 2022-01-31 | 2023-08-03 | Oxurion NV | Plasma kallikrein inhibitor therapy for anti-vegf sensitization |
| WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
| WO2024151615A1 (en) * | 2023-01-10 | 2024-07-18 | The University Of North Carolina At Chapel Hill | Mrna display libraries and methods of use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2176484T3 (en) | 1995-08-18 | 2002-12-01 | Morphosys Ag | PROTEIN BANKS / (POLI) PEPTIDES. |
| US20030166003A1 (en) | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| WO2005122379A2 (en) | 2004-05-27 | 2005-12-22 | The Regents Of The University Of California | Alpha-4 beta-1 integrin ligands for imaging and therapy |
| WO2006078161A1 (en) | 2005-01-24 | 2006-07-27 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| PL2374472T3 (en) * | 2006-03-16 | 2018-11-30 | Dyax Corp. | Compositions and methods for treating ophthalmic disorders |
| ES2560868T3 (en) * | 2006-12-22 | 2016-02-23 | Phadia Ab | Novel prostate calicrein allergen |
| EP2653545A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and compositions |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
| EP2649095B1 (en) * | 2010-12-10 | 2021-10-06 | Aleksander S. Popel | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| WO2013022342A1 (en) * | 2011-08-09 | 2013-02-14 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg | A method of analysing a blood sample of a subject for the presence of a foetal disease or condition marker |
| GB201117428D0 (en) | 2011-10-07 | 2011-11-23 | Bicycle Therapeutics Ltd | Structured polypeptides with sarcosine linkers |
| PL2764140T3 (en) * | 2011-10-07 | 2018-04-30 | Bicyclerd Limited | Modulation of structured polypeptide specificity |
| US20140274759A1 (en) | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
| GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| ES2715379T3 (en) * | 2013-10-28 | 2019-06-04 | Bicyclerd Ltd | Novel Polypeptides |
-
2013
- 2013-04-11 GB GB201306623A patent/GB201306623D0/en not_active Ceased
-
2014
- 2014-04-11 NZ NZ713439A patent/NZ713439A/en unknown
- 2014-04-11 RU RU2015147869A patent/RU2674070C2/en active
- 2014-04-11 EP EP14730083.4A patent/EP2983722B1/en active Active
- 2014-04-11 AU AU2014253036A patent/AU2014253036B2/en active Active
- 2014-04-11 CA CA2908406A patent/CA2908406C/en active Active
- 2014-04-11 PL PL14730083T patent/PL2983722T3/en unknown
- 2014-04-11 SG SG10201805806RA patent/SG10201805806RA/en unknown
- 2014-04-11 DK DK14730083.4T patent/DK2983722T3/en active
- 2014-04-11 SG SG11201508017QA patent/SG11201508017QA/en unknown
- 2014-04-11 CN CN201480030327.1A patent/CN105307686B/en active Active
- 2014-04-11 TR TR2019/03649T patent/TR201903649T4/en unknown
- 2014-04-11 PT PT14730083T patent/PT2983722T/en unknown
- 2014-04-11 JP JP2016506999A patent/JP6588890B2/en active Active
- 2014-04-11 WO PCT/EP2014/057440 patent/WO2014167122A1/en not_active Ceased
- 2014-04-11 ES ES14730083T patent/ES2715406T3/en active Active
- 2014-04-11 US US14/781,294 patent/US10118947B2/en active Active
-
2018
- 2018-06-20 US US16/013,795 patent/US10870679B2/en active Active
-
2019
- 2019-09-13 JP JP2019166728A patent/JP6785932B2/en active Active
-
2020
- 2020-08-07 US US16/987,764 patent/US11753444B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160046673A1 (en) | 2016-02-18 |
| CA2908406C (en) | 2021-07-20 |
| JP6588890B2 (en) | 2019-10-09 |
| US11753444B2 (en) | 2023-09-12 |
| US10118947B2 (en) | 2018-11-06 |
| DK2983722T3 (en) | 2019-04-01 |
| JP2020019778A (en) | 2020-02-06 |
| JP2016519683A (en) | 2016-07-07 |
| JP6785932B2 (en) | 2020-11-18 |
| NZ713439A (en) | 2021-06-25 |
| CN105307686B (en) | 2019-05-28 |
| US20180362585A1 (en) | 2018-12-20 |
| SG10201805806RA (en) | 2018-08-30 |
| AU2014253036A1 (en) | 2015-10-22 |
| AU2014253036B2 (en) | 2019-01-31 |
| ES2715406T3 (en) | 2019-06-04 |
| PT2983722T (en) | 2019-03-25 |
| HK1221172A1 (en) | 2017-05-26 |
| CN105307686A (en) | 2016-02-03 |
| RU2015147869A (en) | 2017-05-16 |
| US20210079043A1 (en) | 2021-03-18 |
| GB201306623D0 (en) | 2013-05-29 |
| US10870679B2 (en) | 2020-12-22 |
| PL2983722T3 (en) | 2019-08-30 |
| EP2983722B1 (en) | 2018-12-12 |
| TR201903649T4 (en) | 2019-04-22 |
| WO2014167122A1 (en) | 2014-10-16 |
| CA2908406A1 (en) | 2014-10-16 |
| EP2983722A1 (en) | 2016-02-17 |
| RU2674070C2 (en) | 2018-12-04 |
| BR112015025699A2 (en) | 2017-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201508017QA (en) | Modulation of structured polypeptide specificity | |
| ZA201604703B (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| SG11201600990VA (en) | Modulation of tumor immunity | |
| ZA201507110B (en) | Crystal modifications of elobixibat | |
| IL244095A0 (en) | Modulators of complement factor b | |
| SG11201400888TA (en) | Modulation of structured polypeptide specificity | |
| LT3461895T (en) | Modulation of ube3a-ats expression | |
| SG11201603028SA (en) | Purification of proteins | |
| GB201312311D0 (en) | Uses of enzyme inhibitors | |
| IL245024A0 (en) | Phenyl linked quinolinyl modulators of ror-gamma-t | |
| GB201205612D0 (en) | Modulation of structured polypeptide specificity | |
| GB201318284D0 (en) | Construction of surfaces | |
| GB201311051D0 (en) | Fastening regions of material together | |
| GB201304608D0 (en) | BenTime of Yisrael operable arrangement | |
| HUP1300278A2 (en) | Ski-truck made of rubber | |
| GB201304569D0 (en) | Toroidal seal |